The Lancet publishes two phase 3 studies on cholesterol-lowering medication
Amgen announced The Lancet published data from two Phase 3 studies, RUTHERFORD-2 and TESLA, that showed treatment with evolocumab, a novel investigational LDL-C-lowering medication, resulted in a statistically significant reduction in LDL-C compared to placebo in patients with different types of FH. October 01, 2014